Borage Seed Oil GLA.

Borage oil is the densest common source of gamma-linolenic acid, so the two supply the identical delta-6 desaturase product. Doses stack directly and should be counted as one GLA intake.

Evening primrose oil carries GLA at roughly a third the concentration of borage. Combining them raises total GLA rather than adding a new mechanism.

GLA elongates to dihomo-gamma-linolenic acid, which can either form series-1 eicosanoids or be desaturated onward to arachidonic acid. Added EPA restrains that onward step and competes at cyclooxygenase, which is why GLA oils are routinely formulated with marine omega-3.

Fish oil supplies EPA and DHA that occupy the same elongation and cyclooxygenase machinery as the GLA pathway. The pairing keeps dihomo-gamma-linolenic acid accumulating rather than moving toward arachidonic acid.

GLA has three double bonds and oxidises readily in the capsule and in membranes. Alpha-tocopherol interrupts lipid peroxidation chains, which is why it is standard in every polyunsaturated oil softgel.

Delta-6 desaturase converts linoleic acid to GLA and depends on zinc for normal activity. Adequate zinc supports the endogenous route that borage oil bypasses, and supports downstream handling of the fatty acid.

Pyridoxine is required for normal desaturase and elongase activity in the essential fatty acid pathway. It is a standard companion in GLA formulas for that reason.

Ginkgolides antagonise platelet activating factor, and GLA-derived series-1 eicosanoids also damp platelet aggregation. Stacking both nudges normal clotting in the same direction, so combined use warrants care around procedures.

Black currant seed oil carries both GLA and stearidonic acid, so it overlaps with borage on the same pathway. Total GLA should be counted across both.

Gamma-linolenic acid is what the body makes from linoleic acid when delta-6 desaturase inserts a double bond, and supplying GLA directly bypasses that step. Since the desaturase is the slow point of the sequence, the two occupy the same pathway at different positions. Adding more linoleic acid alongside GLA does not push the pathway further, because the enzyme rather than the substrate is the constraint.

Delta-6 desaturase handles both fatty acid families and prefers alpha-linolenic acid, so a large flaxseed oil intake reduces the desaturation of omega-6 substrates. That competition works on the conversion step, not on the absorption of preformed GLA. Someone taking both is running two substrates into one enzyme, which is a genuine interaction rather than a caution.

GLA is elongated to dihomo-gamma-linolenic acid, and part of that pool can be desaturated onward to arachidonic acid by delta-5 desaturase. Long chain omega-3 fatty acids restrain that enzyme, so co-supplying them keeps more of the pool at the DGLA stage. This is the mechanistic reason GLA and marine oils are so often formulated together, and the readouts are membrane fatty acid and eicosanoid markers.

A highly unsaturated oil oxidises through a chain reaction once initiated, and tocopherols interrupt that chain inside the oil itself. Nearly every borage softgel therefore contains added tocopherol, whether declared as an ingredient or as an antioxidant. The role is protecting the delivered fatty acid, not adding a separate physiological action.

Rosemary extract supplies carnosic acid and rosmarinic acid, phenolic antioxidants used industrially to slow oxidation in pressed oils. A 2025 study of herbal maceration in cold-pressed oils measured retained antioxidant activity across storage, which is a stability endpoint rather than a physiological one. In a borage oil formula rosemary is a preservation partner.

Borage oil is a triglyceride, so its GLA reaches the bloodstream only after pancreatic lipase clips the fatty acids from the glycerol backbone within bile salt micelles. Where lipase output or bile flow is low, absorption of any oil falls. This is why oil capsules are usually taken with a meal containing fat.

Without adequate bile salts, oil stays in large droplets that lipase cannot work on efficiently, and fatty acid uptake drops. Supplemental bile components are used where bile output is a known limitation. The interaction concerns delivery of the oil, and it applies to any triglyceride oil rather than to GLA specifically.

Lecithin lowers interfacial tension so an oil disperses into fine droplets, which increases the surface area lipase can act on and lets an oil be built into an emulsion or a powder. It is a delivery choice rather than an added action. Sunflower-derived lecithin is used where a soy-free label is wanted.

Delta-6 desaturase activity depends on a set of cofactors including magnesium and zinc, alongside vitamin B6 and niacin in the wider pathway. That dependency matters for converting linoleic acid to GLA, and less for preformed GLA taken directly. It is worth stating as a pathway requirement rather than as a reason to expect an additional effect.

Astaxanthin sits in the same lipid environment as the polyunsaturated fatty acids it might protect, spanning membranes rather than sitting at one end. In an oil formula that gives a second antioxidant alongside tocopherol, working by a different chemistry. Support for this pairing is assay-level and formulation-level, not clinical.

Leukotriene B4 is a 5-lipoxygenase product, and both inputs touch that branch: boswellic acids act on the enzyme, while borage oil changes the fatty acid substrate pool available to it. One ex vivo study in isolated neutrophils reported lower leukotriene B4 generation after borage supplementation, which is a cell-level marker rather than a clinical result. No trial of the two together appears in this candidate set, so the pairing is inference from shared pathway.

Curcumin acts largely through NF-kappaB-linked transcription of inflammatory mediators, while GLA works by changing which fatty acids are available for eicosanoid synthesis. The two therefore act at different levels of the same output, which is the rationale for combining them in joint comfort formulas. The support is mechanistic and marker-based, and no combination trial appears here.

GLA is elongated to DGLA, which yields prostaglandin E1, a mediator that reduces platelet aggregation. Willow bark salicylates act on the same function through cyclooxygenase. Effects in the same direction can add, so this is a pairing to flag for anyone already tracking bleeding tendency or taking other agents that affect platelets, and it should be raised with a clinician rather than treated as a benefit.